# Extension Study of MT-1303 in Subjects With Crohn's Disease

> **NCT02389790** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 46 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** MT-1303

## Key facts

- **NCT ID:** NCT02389790
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389790, "Extension Study of MT-1303 in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02389790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*